Two Stocks in Concentration: Annaly Capital Management, Incorporated (NYSE:NLY), Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Annaly Capital Management, Inc. (NYSE:NLY)

The company announced its last quarter financial performance results on 11/02/2016. Annaly Capital Management, Inc. (NYSE:NLY) belongs to Finance sector that declined -1.46% in value when last trading session closed at $10.12. The company has a market capitalization of $10.34 Billion. The company’s stock has a Return on Assets (ROA) of 0.2 percent, a Return on Equity (ROE) of 1.6 percent and Return on Investment (ROI) of 0.6 percent. The company reached its 52-Week high of $11.29 on Aug 10, 2016 and 52-Week low of $8.73 on Jan 22, 2016.

Earnings per share (ttm) for Annaly Capital Management, Inc. (NYSE:NLY) according to Finviz Data is $0.12.

The growth estimate for Annaly Capital Management, Inc. (NYSE:NLY) for the current quarter is -12.1 percent. The projected growth estimate for the next quarter is -3.3 percent. The company’s stock has grown by -10.36 percent in the past 5 years. For the next 5 years, the company is expected to grow by -5.3 percent.

This company was Downgrade by FBR & Co. on 20-Dec-16  to Mkt Perform.

The 10 analysts offering 12-month price forecasts for Annaly Capital Management Inc have a median target of 10.25, with a high estimate of 12.00 and a low estimate of 8.00. The median estimate represents a +1.28% increase from the last price of 10.12.

Financial History:

Following Earnings result, share price were UP 12 times out of last 24 Qtrs. In the last 27 earnings reports, the company has topped earnings-per-share estimates 41% percent of times. It has met expectations  2  times and missed earnings  5  times.

The consensus recommendation for Annaly Capital Management, Inc. (NYSE:NLY) is 3.33. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. The consensus recommendation 30 days ago for this company stood at 3. In comparison, the consensus recommendation 60 days ago was at 3, and 90 days ago was at 3 respectively.

Future Expectations:

When the current quarter ends, Wall Street expects Annaly Capital Management, Inc. to have earnings per share of $0.29.

Revenue is expected to range from 507 Million to 578.4 Million with an average of 555.98 Million.

Company Profile:

Annaly Capital Management, Inc. owns, manages, and finances a portfolio of real estate related investment securities, including mortgage pass-through certificates, collateralized mortgage obligations (or CMOs) and agency callable debentures. Annaly also manages other securities representing interests in or obligations backed by pools of mortgage loans. The Company wholly-owned subsidiaries offer diversified real estate, asset management and other financial services. Annaly’s principal business objective is to generate net income for distribution to investors from its Investment Securities and from dividends it receives from its subsidiaries. Annaly is a Maryland corporation that has elected to be taxed as a real estate investment trust (REIT).

Teva Pharmaceutical Industries Limited (NYSE:TEVA):

Teva Pharmaceutical Industries Limited (NYSE:TEVA) belongs to Medical sector closed its last session with a loss of -1.85 percent and closed its previous trading session at $33.47. According to Finviz reported data, the stock currently has Earnings per Share (EPS) (ttm) of $1.73. The company has the Market capitalization of $33.97 Billion. The company’s stock has a Return on Assets (ROA) of 2.4 percent, a Return on Equity (ROE) of 5.7 percent and Return on Investment (ROI) of 5.7 percent. The company reached its 52-Week high of $64.31 on Jan 25, 2016 and 52-Week low of $33.46 on Jan 19, 2017.

The growth estimate for Teva Pharmaceutical Industries Limited (NYSE:TEVA) for the current quarter is 6.2 percent. The projected growth estimate for the next quarter is -2.5 percent. The company’s stock has grown by -0.84 percent in the past 5 years. For the next 5 years, the company is expected to grow by 1.11 percent.

This company was Downgrade by Wells Fargo on 9-Jan-17 to Market Perform.

The 24 analysts offering 12-month price forecasts for Teva Pharmaceutical have a median target of 47.50, with a high estimate of 100.00 and a low estimate of 37.00. The median estimate represents a +41.92% increase from the last price of 33.47.

Financial History:

Following Earnings result, share price were DOWN 13 times out of last 19 Qtrs. In the last 27 earnings reports, the company has topped earnings-per-share estimates 75% percent of times. It has met expectations  2  times and missed earnings  1 times.

The consensus recommendation for Teva Pharmaceutical Industries Limited (NYSE:TEVA) is 2.19. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. The consensus recommendation 30 days ago for this company stood at 2. In comparison, the consensus recommendation 60 days ago was at 1.79, and 90 days ago was at 1.59 respectively.

Future Expectations:

When the current quarter ends, Wall Street expects Teva Pharmaceutical Industries Limited to have earnings per share of $1.36.

Revenue is expected to range from 6.08 Billion to 6.39 Billion with an average of 6.26 Billion.

Company Profile:

TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals.  Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies.  The company markets a variety of dosage forms, including both extended and immediate release tablets and capsules, creams, ointments, solutions, and suspensions.  Key therapeutic areas are the analgesic, anti-infective, cardiovascular, CNS, dermatological and anti-inflammatory categories.